Urinary smooth muscle sarcoma in a labrador retriever

Publication date: January 2019Source: Journal of Comparative Pathology, Volume 166Author(s): T. Soare, L. Ressel, B. Bofan, S. Sarbovan, M. Militaru
Source: Journal of Comparative Pathology - Category: Pathology Source Type: research

Related Links:

ConclusionIntratumoral heterogeneity on MRI quantitatively displayed by histogram parameters can differentiate STS of different grades. Skewness and kurtosis on ER maps show the capacity.
Source: European Journal of Radiology - Category: Radiology Source Type: research
Transcription factor fusion genes create oncoproteins that drive oncogenesis and represent challenging therapeutic targets. Understanding the molecular targets by which such fusion oncoproteins promote malignancy offers an approach to develop rational treatment strategies to improve clinical outcomes. Capicua–double homeobox 4 (CIC-DUX4) is a transcription factor fusion oncoprotein that defines certain undifferentiated round cell sarcomas with high metastatic propensity and poor clinical outcomes. The molecular targets regulated by the CIC-DUX4 oncoprotein that promote this aggressive malignancy remain largely unknow...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Conditions:   Metastatic Soft Tissue Sarcoma;   Advanced Soft Tissue Sarcoma Intervention:   Drug: doxorubicin with AGEN1884 and AGEN2034 Sponsors:   University of Colorado, Denver;   National Cancer Institute (NCI);   Agenus Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Adenocarcinoma;   Adenocystic Carcinoma;   Anal Cancer;   Appendix Cancer;   Brain Tumor;   Glioblastoma;   Astrocytoma;   Bile Duct Cancer;   Cholangiocarcinoma;   Bladder Cancer;   Bone Cancer;   Synovial Sarcoma;   Chondrosarcoma;   Liposarcoma;   Sarcoma, Kaposi;   S arcoma,Soft Tissue;   Sarcoma;   Osteosarcoma;   CNS Cancer;   Brain Stem Neoplasms;   Breast Cancer;   Cervical Cancer;   Colorectal Cancer; &n...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Metastatic Soft Tissue Sarcoma;   Advanced Soft Tissue Sarcoma Intervention:   Drug: doxorubicin with AGEN1884 and AGEN2034 Sponsors:   University of Colorado, Denver;   National Cancer Institute (NCI);   Agenus Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
(UNC Lineberger Comprehensive Cancer Center) UNC Lineberger Comprehensive Cancer Center researchers have discovered a hyperactive cell signal that contributes to tumor growth in primary effusion lymphoma, an aggressive type of non-Hodgkin lymphoma caused by infection with the Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8). They also reported in the PNAS paper that they've developed an experimental therapeutic, UNC3810A, to block the signal and slow tumor growth.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
AbstractLiposome is one of the oldest yet most successful nanomedicine platforms. Doxil ®, PEGylated liposome loaded with doxorubicin (DOX), was approved by the FDA in 1995 for the treatment of AIDS-related Kaposi’s sarcoma, and it was the first approval for nanomedicine. Since then, liposome-based therapeutics were approved for the treatment of various diseases and many clinical tr ials are underway. The success of the liposome-based therapeutics was due to following factors: (1) ease of synthesis, (2) biocompatibility, (3) the ability to load both hydrophilic and hydrophobic agents, and (4) long circulation pro...
Source: Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
Authors: Bhasin A, Singal RK, Agarwal A, Qureshi S, Anand G, D C, Sachan S PMID: 31321939 [PubMed - in process]
Source: Journal of the Association of Physicians of India - Category: General Medicine Tags: J Assoc Physicians India Source Type: research
Authors: Wang Y, Song Z, Leng P, Liu Y Abstract Serum deprivation response (SDPR) gene has been recently characterized as a gene signature marker or serving a tumor suppressor role in specific types of cancer. However, gene expression alterations of SDPR in various types of cancer and their relevance to clinical outcomes remain unclear. In the present study, SDPR expression was profiled using the Oncomine database, and SDPR downregulation was indicated in most types of cancer. In agreement with previously reported breast cancer cases, downregulation of SDPR was indicated to be significantly associated with poor sur...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Condition:   Sarcoma Intervention:   Drug: chidamide and toripalimab Sponsor:   Sun Yat-sen University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Pathology | Sarcomas